Treatment of dysthymia.
Buni
T M
TM
University of Virginia, Health Sciences Center, Charlottesville, USA. dslawson@virginia.edu
D015057:1-Naphthylamine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D019263:Dysthymic Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007099:Imipramine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D020280:Sertraline; D016896:Treatment Outcome
D015057:1-Naphthylamine; D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D007099:Imipramine; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline